SEP 4, 2026 · PHASE 1/2 TRIAL
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
ClinicalTrials.gov
This is a Phase I/II trial registration with no posted results; it is actively enrolling to establish safety, tolerability, and preliminary efficacy in a novel radiopharmaceutical combination.
Reported
Planned enrollment20
Study phasePhase I/II
Primary outcome (Phase I)Incidence and severity of dose-limiting tox…